Form 4: Acrivon Therapeutics Chief Legal Officer Reports Tax Withholding Transaction
SEC Form 4 Filing
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon the vesting of restricted stock units.
Summary
- On July 17, 2024, Mary Miller, the Chief Legal Officer of Acrivon Therapeutics, Inc., reported a transaction on Form 4.
- The transaction involved the withholding of 558 shares of common stock to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- The price per share for the withholding was $7.69.
- Following the transaction, Miller directly owns 39,151 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to tax withholding, and does not contain any information that would significantly impact investor sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.
Key Dates
| Date | Description |
|---|---|
| 07/17/2024 | Date of the transaction involving the withholding of shares for tax obligations. |
| 07/19/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.